MUSTANG BIO, INC. Proceeds from Issuance of Debt
MUSTANG BIO, INC. (MBIO) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2024-03-11
- MUSTANG BIO, INC. proceeds from issuance of debt for the quarter ending 2023-12-31 was $0.00.
- MUSTANG BIO, INC. proceeds from issuance of debt for the quarter ending 2023-09-30 was $0.00.
- MUSTANG BIO, INC. proceeds from issuance of debt for the quarter ending 2023-06-30 was $0.00.
- MUSTANG BIO, INC. proceeds from issuance of debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. proceeds from issuance of debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- MUSTANG BIO, INC. proceeds from issuance of debt for fiscal 2022 was $30.00M.
- MUSTANG BIO, INC. proceeds from issuance of debt for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | $0.00 10-K · filed 2024-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | $0.00 derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | $0.00 derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | $30.00M 10-K · filed 2024-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $30.00M 10-Q · filed 2023-11-14 | $30.00M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $30.00M 10-Q · filed 2023-08-14 | $30.00M derived: sum of 3 quarters · filed 2023-08-14 | $30.00M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $30.00M 10-Q · filed 2023-05-12 | $30.00M derived: sum of 2 quarters · filed 2023-05-12 | $30.00M derived: sum of 3 quarters · filed 2023-05-12 | $30.00M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |